T1D, Metabolic Syndrome and Insulin Resistance
Clinical Characteristics in Adults With Type 1 Diabetes, Metabolic Syndrome and Insulin Resistance
1 other identifier
observational
19
1 country
1
Brief Summary
Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico. The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez"; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria. Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2022
CompletedFirst Submitted
Initial submission to the registry
August 13, 2022
CompletedFirst Posted
Study publicly available on registry
August 16, 2022
CompletedAugust 19, 2022
August 1, 2022
7 months
August 13, 2022
August 16, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Glycated hemoglobin
Concentrations by an enzymatic immunoassay method
March 2022
Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols
Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics
March 2022
Eligibility Criteria
Patients who attend Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez", previously diagnosed with type 1 diabetes
You may qualify if:
- At least six months after being diagnosed with T1D
You may not qualify if:
- Did not attend regular consultations
- Did not agree to participate or to give a blood sample
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Isela Esther Juarez Rojop
Villahermosa, Tabasco, 86090, Mexico
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Full-Time Investigator Professor
Study Record Dates
First Submitted
August 13, 2022
First Posted
August 16, 2022
Study Start
August 1, 2021
Primary Completion
February 15, 2022
Study Completion
March 1, 2022
Last Updated
August 19, 2022
Record last verified: 2022-08